Most importantly, in vitro experiments with two PAAD cell lines (BxPC-3 and AsPC-1) also consistently illustrated that cell sensitivity to 5-fluorouracil was observably enhanced after knockdown of ITGB6, indicating that our precision treatment strategy for PAAD derived from pharmacogenomic-based subtypes has good prospects. The gene discussed is ITGB6; the disease is pancreatic adenocarcinoma.